ArticleJCI insight2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.
Article in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Case report: A case series report: recurrent urolithiasis as a risk factor for upper tract urothelial carcinoma.Frontiers in oncology · 2026Article
- Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies.Cancer research communications · 2025Article
- The genomic and transcriptomic landscape of metastastic urothelial cancer.Nature communications · 2024Article
- Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?Translational andrology and urology · 2024Article
- Research autopsy programmes in oncology: shared experience from 14 centres across the world.The Journal of pathology · 2024Article
- The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.Nature communications · 2024Article
- A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.Nature genetics · 2024Article
- Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.Clinical genitourinary cancer · 2023Article
- Review
- Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.Cancer cell · 2023Article
- Article
- The dynamic roles of the bladder tumour microenvironment.Nature reviews. Urology · 2022Review
- Urine Cellular DNA Point Mutation and Methylation for Identifying Upper Tract Urinary Carcinoma.Cancers · 2022Article
- mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation.JCI insight · 2021Article
- A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.Scientific reports · 2021Article
- Review
- Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Nature communications · 2021Article
- Two cases of osteoblastic bone metastasis from muscle-invasive bladder cancer with discrepancy in response to chemotherapy: problems and limitations of bone biopsy.International cancer conference journal · 2020Article
- [Adjuvant chemotherapy in the treatment of urothelial carcinoma of the upper urinary tract].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundLittle is known about the genomic differences between metastatic urothelial carcinoma (LTUC) and upper tract urothelial carcinoma (UTUC). We compare genomic features of primary and metastatic UTUC and LTUC tumors in a cohort of patients with end stage disease.
methodsWe performed whole exome sequencing on matched primary and metastatic tumor samples (N=37) from 7 patients with metastatic UC collected via rapid autopsy. Inter- and intra-patient mutational burden, mutational signatures, predicted deleterious mutations, and somatic copy alterations (sCNV) were analyzed.
resultsWe investigated 3 patients with UTUC (3 primary samples, 13 metastases) and 4 patients with LTUC (4 primary samples, 17 metastases). We found that sSNV burden was higher in metastatic LTUC compared to UTUC. Moreover, the APOBEC mutational signature was pervasive in metastatic LTUC and less so in UTUC. Despite a lower overall sSNV burden, UTUC displayed greater inter- and intra-individual genomic distances at the copy number level between primary and metastatic tumors than LTUC. Our data also indicate that metastatic UTUC lesions can arise from small clonal populations present in the primary cancer. Importantly, putative druggable mutations were found across patients with the majority shared across all metastases within a patient.
conclusionsMetastatic UTUC demonstrated a lower overall mutational burden but greater structural variability compared to LTUC. Our findings suggest that metastatic UTUC displays a greater spectrum of copy number divergence from LTUC. Importantly, we identified druggable lesions shared across metastatic samples, which demonstrate a level of targetable homogeneity within individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.